18 related articles for article (PubMed ID: 23164713)
1. Synthesis and evaluation of novel potent HCV NS5A inhibitors.
Zhang H; Zhou L; Amblard F; Shi J; Bobeck DR; Tao S; McBrayer TR; Tharnish PM; Whitaker T; Coats SJ; Schinazi RF
Bioorg Med Chem Lett; 2012 Jul; 22(14):4864-8. PubMed ID: 22704887
[TBL] [Abstract][Full Text] [Related]
2. Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection.
Zhang W; Liu S; Maiga RI; Pelletier J; Brown LE; Wang TT; Porco JA
J Am Chem Soc; 2019 Jan; 141(3):1312-1323. PubMed ID: 30590924
[TBL] [Abstract][Full Text] [Related]
3. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy.
Sakamoto H; Okamoto K; Aoki M; Kato H; Katsume A; Ohta A; Tsukuda T; Shimma N; Aoki Y; Arisawa M; Kohara M; Sudoh M
Nat Chem Biol; 2005 Nov; 1(6):333-7. PubMed ID: 16408072
[TBL] [Abstract][Full Text] [Related]
4. Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors.
Kang IJ; Wang LW; Hsu SJ; Lee CC; Lee YC; Wu YS; Yueh A; Wang JC; Hsu TA; Chao YS; Chern JH
Bioorg Med Chem Lett; 2009 Nov; 19(21):6063-8. PubMed ID: 19796940
[TBL] [Abstract][Full Text] [Related]
5. Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.
Krueger AC; Madigan DL; Beno DW; Betebenner DA; Carrick R; Green BE; He W; Liu D; Maring CJ; McDaniel KF; Mo H; Molla A; Motter CE; Pilot-Matias TJ; Tufano MD; Kempf DJ
Bioorg Med Chem Lett; 2012 Mar; 22(6):2212-5. PubMed ID: 22342631
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors.
Kang IJ; Wang LW; Yeh TK; Lee CC; Lee YC; Hsu SJ; Wu YS; Wang JC; Chao YS; Yueh A; Chern JH
Bioorg Med Chem; 2010 Sep; 18(17):6414-21. PubMed ID: 20675142
[TBL] [Abstract][Full Text] [Related]
7. A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure-activity relationships and anti-HCV activity in GS4.3 replicon cells.
Shan GZ; Peng ZG; Li YH; Li D; Li YP; Meng S; Gao LY; Jiang JD; Li ZR
J Antibiot (Tokyo); 2011 Feb; 64(2):177-82. PubMed ID: 21179047
[TBL] [Abstract][Full Text] [Related]
8. Enantioselective synthesis of derivatives and structure-activity relationship study in the development of NA255 as a novel host-targeting anti-HCV agent.
Kawasaki K; Masubuchi M; Hayase T; Komiyama S; Watanabe F; Fukuda H; Murata T; Matsubara Y; Koyama K; Shindoh H; Sakamoto H; Okamato K; Ohta A; Katsume A; Aoki M; Aoki Y; Shimma N; Sudoh M; Tsukuda T
Bioorg Med Chem Lett; 2013 Jan; 23(1):336-9. PubMed ID: 23164713
[TBL] [Abstract][Full Text] [Related]
9. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
